Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $5.0 million.

  • Anika Therapeutics' Free Cash Flow rose 3113.16% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $648000.0, marking a year-over-year increase of 18019.8%. This contributed to the annual value of -$2.3 million for FY2024, which is 6769.23% up from last year.
  • As of Q3 2025, Anika Therapeutics' Free Cash Flow stood at $5.0 million, which was up 3113.16% from -$1.7 million recorded in Q2 2025.
  • Anika Therapeutics' Free Cash Flow's 5-year high stood at $5.7 million during Q3 2023, with a 5-year trough of -$9.8 million in Q2 2023.
  • Over the past 5 years, Anika Therapeutics' median Free Cash Flow value was $275000.0 (recorded in 2024), while the average stood at -$473473.7.
  • Per our database at Business Quant, Anika Therapeutics' Free Cash Flow plummeted by 103198.76% in 2021 and then skyrocketed by 46424.36% in 2023.
  • Quarter analysis of 5 years shows Anika Therapeutics' Free Cash Flow stood at $3.3 million in 2021, then tumbled by 161.23% to -$2.0 million in 2022, then surged by 187.79% to $1.8 million in 2023, then tumbled by 84.71% to $275000.0 in 2024, then surged by 1712.0% to $5.0 million in 2025.
  • Its Free Cash Flow was $5.0 million in Q3 2025, compared to -$1.7 million in Q2 2025 and -$3.0 million in Q1 2025.